Tscan Therapeutics Inc (TCRX) — Cash Flow Reinvestment Rate
Latest as of September 2023:
7.84x
Tscan Therapeutics Inc (TCRX) has a Cash Flow Reinvestment Rate of 7.84x as of September 2023, reinvesting $62.83 Million (capex $1.42 Million plus investments $-61.41 Million) from operating cash flow of $8.02 Million. See TCRX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
7.84x
(Capex + Investments) / Operating CF
Total Reinvested
$62.83 Million
Capex + Investments
Operating Cash Flow
$8.02 Million
USD
Capital Expenditures
$1.42 Million
USD
Annual Cash Flow Reinvestment Rate for Tscan Therapeutics Inc (None–None)
Year-by-year capital reinvestment analysis for Tscan Therapeutics Inc. See Tscan Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow